BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/26/2023 9:50:16 AM | Browse: 89 | Download: 327
 |
Received |
|
2023-02-19 10:35 |
|
Peer-Review Started |
|
2023-02-19 10:35 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-03-01 07:47 |
|
Revised |
|
2023-03-11 09:24 |
|
Second Decision |
|
2023-04-07 01:03 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-04-07 02:20 |
|
Articles in Press |
|
2023-04-07 02:20 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-05-18 02:59 |
|
Publish the Manuscript Online |
|
2023-05-26 09:50 |
| ISSN |
1948-9366 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yi-Ling Jiang, Xue-Yuan Fu and Zhi-Hui Yin |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Zhi-Hui Yin, MM, Associate Chief Physician, Department of Anorectal, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Avenue, Shigu District, Hengyang 421001, Hunan Province, China. yinzhihui6996@163.com |
| Key Words |
Olaparib; Bevacizumab; Advanced colorectal cancer; Efficacy |
| Core Tip |
Colorectal cancer (CRC) presents insignificant symptoms in the early stage and is commonly diagnosed in the middle and advanced stages. Therefore, surgery is usually not viable because the best timing is missed, and chemotherapy, targeted therapies and other regimens are often utilized as interventions. Olaparib and bevacizumab are common targeted therapies with excellent therapeutic effects in a variety of solid tumors. This research collected the clinical data of 82 patients with advanced CRC, retrospectively investigated the clinical efficacy and safety of olaparib combined with bevacizumab in advanced CRC treatment, and analyzed the effect of this treatment regimen on the serum levels of vascular endothelial growth factor, matrix metalloprotein-9, cyclooxygenase-2, and related tumor markers. |
| Publish Date |
2023-05-26 09:50 |
| Citation |
Jiang YL, Fu XY, Yin ZH. Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer. World J Gastrointest Surg 2023; 15(5): 906-916 |
| URL |
https://www.wjgnet.com/1948-9366/full/v15/i5/906.htm |
| DOI |
https://dx.doi.org/10.4240/wjgs.v15.i5.906 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
